ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年06月09日 10時00分
Source:
Eisai
エーザイ、2023年3月期業績予想(IFRS)の修正に関するお知らせ
東京, 2022年06月09日 - (JCN Newswire) - 直近の業績の動向等を踏まえ、2022年5月13日に公表した2023年3月期(2022年4月1日から2023年3月31日)の業績予想を下記のとおり修正しますのでお知らせします。
1. 2023年3月期の連結業績予想数値の修正(2022年4月1日から2023年3月31日)
※ご参照
https://www.eisai.co.jp/news/2022/news202246.html
2. 修正の理由
当期において、当社が保有する一部株式について株式譲渡益10億円が発生する見込みです。加えて、当社の資本政策の一環としてグローバルな資金配分の最適化を企図し、米国の連結子会社から資金を回収するために当社が米国子会社から払込資本の払戻しを受けた結果、税務上の譲渡損失等が当社にて発生し、法人所得税が従来の想定を下回ることを見込んでいます。これらにより、当期利益を前回予想から115億円増の580億円、親会社の所有者に帰属する当期利益を前回予想から115億円増の570億円に修正します。ROE(親会社所有者帰属持分当期利益率)は7.5%を見込みます。
売上収益、営業利益については、前回予想から変更ありません。
なお、1株当たり160円の年間配当金(第2四半期末80円、期末80円)の予定に変更はありません。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202246.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development
Dec 26, 2024 09:47 JST
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations
Dec 24, 2024 10:54 JST
GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China
Dec 24, 2024 10:23 JST
Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park
Dec 24, 2024 10:10 JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 17:22 JST
Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration
Dec 23, 2024 13:30 JST
Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia
Dec 20, 2024 17:35 JST
Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport
Dec 20, 2024 17:24 JST
Toyota Launches Alphard and Vellfire PHEV Models in Japan
Dec 20, 2024 15:38 JST
6G Begins! Embarking on a New Journey of Global Interoperable Standards
Dec 19, 2024 16:50 JST
MI LNG Company to Change Corporate Name to MILES
Dec 19, 2024 13:49 JST
Two Honda 0 Series Prototype Models to Premiere at CES 2025
Dec 19, 2024 12:30 JST
Honda Presents World Premiere of Honda S+ Shift, Next-generation e:HEV Technology
Dec 19, 2024 12:13 JST
NEC Completes new Asia Pacific submarine cable
Dec 19, 2024 12:02 JST
Enablement of JCB Contactless Payment at All NJ TRANSIT Contactless Bus and Light Rail Validators in New Jersey, New York, and Pennsylvania
Dec 19, 2024 12:00 JST
Honda Presents Next-generation e:HEV Technologies at Press Briefing on Honda e:HEV Business and Technology
Dec 18, 2024 17:50 JST
More Latest Release >>
Related Release
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/28/2024 4:26:00 PM JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
11/20/2024 11:51:00 AM JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
11/20/2024 10:24:00 AM JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
More Press release >>